Neuroendocrine carcinoma
MONDO:0002120A malignant neuroendocrine neoplasm composed of cells containing secretory granules that stain positive for NSE and chromogranin. The neoplastic cells are often round and form clusters or trabecular sheets. Representative examples are small cell carcinoma, large cell neuroendocrine carcinoma, and Merkel cell carcinoma.
Also known as: NEC, neuroendocrine cancer, neuroendocrine carcinoma
3427 clinical trials for this condition and its sub-types, 106 tagged with Neuroendocrine carcinoma itself.
Follow this condition to get notified about new trialsWhere it sits in the disease tree
Browse by category →Sub-types of Neuroendocrine carcinoma
-
Small cell carcinoma 26 trials · 542 incl. sub-types
18 sub-types
- Small cell lung carcinoma 514 trials · 515 incl. sub-types Sub-types →
- Prostate small cell carcinoma 9 trials
- Urinary bladder small cell neuroendocrine carcinoma 9 trials
- Cervical small cell carcinoma 4 trials
- Esophageal small cell neuroendocrine carcinoma 2 trials
- Ovarian small cell carcinoma 1 trial · 2 incl. sub-types Sub-types →
- Ureter small cell carcinoma 1 trial
- Bartholin gland small cell carcinoma 0 trials
- Ampulla of vater small cell neuroendocrine carcinoma 0 trials
- Colon small cell neuroendocrine carcinoma 0 trials
- Endometrial small cell carcinoma 0 trials
- Extrahepatic bile duct small cell adenocarcinoma 0 trials
- Gallbladder small cell neuroendocrine carcinoma 0 trials
- Gastric small cell neuroendocrine carcinoma 0 trials
- Laryngeal small cell carcinoma 0 trials
- Pancreatic small cell neuroendocrine carcinoma 0 trials
- Salivary gland small cell carcinoma 0 trials
- Thymus small cell carcinoma 0 trials
-
Cutaneous neuroendocrine carcinoma 78 trials
-
Medullary thyroid gland carcinoma 42 trials · 53 incl. sub-types
1 sub-type
- Familial medullary thyroid carcinoma 23 trials
-
Large cell neuroendocrine carcinoma 12 trials · 31 incl. sub-types
6 sub-types
- Pulmonary large cell neuroendocrine carcinoma 20 trials Sub-types →
- Cervical large cell neuroendocrine carcinoma 4 trials
- Breast large cell neuroendocrine carcinoma 0 trials
- Ovarian large-cell neuroendocrine carcinoma 0 trials
- Pancreatic large cell neuroendocrine carcinoma 0 trials
- Thymic large cell neuroendocrine carcinoma 0 trials
-
Pancreatic endocrine carcinoma 12 trials
2 sub-types
-
Malignant adrenal gland pheochromocytoma 11 trials
-
Liver neuroendocrine carcinoma 3 trials
2 sub-types
-
Thymic neuroendocrine carcinoma 3 trials
5 sub-types
-
Goblet cell carcinoma 2 trials
-
1 sub-type
-
Combined lung carcinoma 0 trials · 1 incl. sub-types
2 sub-types
-
Vulvar neuroendocrine carcinoma 0 trials
1 sub-type
- Bartholin gland small cell carcinoma 0 trials
Most studied deeper sub-types
-
New hope for rare, aggressive cancers: immune therapy targets hard-to-treat tumors
Disease control Stopped earlyThis study tests a drug called tarlatamab, which helps the immune system find and attack cancer cells. It is for people with advanced neuroendocrine carcinomas of the digestive system or unknown origin, a rare and aggressive cancer with limited treatment options. About 87 partici…
Phase 2 • Sponsor: Grupo Espanol de Tumores Neuroendocrinos • Aim: Disease control
Last updated Sep 20, 2026 00:00 UTC
-
Promising cancer drug falls short in rare tumor trial
Disease control Stopped earlyThis study tested the drug TAS-102 (also known as Lonsurf) in 14 people with a rare and aggressive type of neuroendocrine cancer that started outside the lungs. The goal was to see if the drug could shrink tumors or improve survival. The trial was stopped early, so results are li…
Phase 2 • Sponsor: Baylor Research Institute • Aim: Disease control
Last updated Jun 27, 2026 07:56 UTC
-
Cancer drug trial halted early: what we know
Disease control Stopped earlyThis study tested a new drug called INCB059872 in people with advanced solid tumors or blood cancers that had not responded to standard treatments. The goal was to find a safe dose and see if it could control the disease. The trial was stopped early, so results are limited.
Phase 1/2 • Sponsor: Incyte Corporation • Aim: Disease control
Last updated Jun 27, 2026 07:56 UTC